Mens Health Week 2020: Prostate cancer and other common health problems in Indian men; how to prevent them  |  Photo Credit: iStock Images

New Delhi: Its Men s Health Week, which is observed every year leading up to Fathers Day. The main objective of the week is to raise awareness of health problems that are preventable as well as encourage early detection and treatment of diseases that affect men and boys. Experts say only 30 per cent of a mans overall health is determined by his genetics, and 70 per cent is controllable through his lifestyle. Studies show that men live almost 9 years in poor health in their lifetime - which can be prevented by making small lifestyle changes.

The observance is a reminder for men to take steps for a healthier, longer life - yet, they do not have to do it alone. All of us can help support the health and safety of the men in our lives - whether its your husband, son, dad, brother, or friend. The 2020 Mens Health Week is being observed amid the novel coronavirus pandemic, hence, the theme, Take Action on Covid-19. This year, the week runs from 15-21 June. On the occasion of Mens Health Week, Dr Govardhan Reddy, Lead Consultant - Urology and Uro Oncology, Aster CMI Hospital, Bangalore, talked about the common health problems that affect Indian men and what they can do to prevent them.

Some of the common health issues plaguing Indian men include - prostate cancer, erectile dysfunction, infertility and impotency, heart disease, etc. Apart from this, comorbidities like diabetes, hypertension, obesity, cancer and mental health disorders with daily alcohol intake are some of the largest gender health gaps.

Available evidence indicates that young people are prone to a number of conditions due to personal choices, environmental influences and lifestyle changes. Nutritional disorders (both malnutrition and over-nutrition), tobacco use, harmful alcohol use, other substance use, high-risk sexual behaviors, stress, common mental disorders, and injuries (road traffic injuries, suicides, and violence of different types) specifically affect this population and it has a long-lasting impact.

Talking about prostate cancer, it is advisable for men with a family history ofthe condition to undergo a mandatory screening with the consultant urologist after the age of 45 regardless of any symptoms which comprise of frequent and difficult urination, weak urine stream, blood in semen, pelvic pain or stiffness and erectile dysfunction.

Renal transplant surgeons stress on the use of tobacco as the main cause for cancers in kidney and bladder. Smoking or vaping is also harmful to erectile functions and increases male infertility.

Also, people working in the tar and painting industries or factories carry high risk for bladder cancers. Similarly, fatty diets are known to cause a higher risk for prostate cancer and stone diseases, in order to prevent them it is better to have 2-3 litres of water per day.

Fortunately, many of mens health issues can be prevented or treated if diagnosed early. Here are a few things men can do to prevent or reduce their risk of common health problems:

Making healthier lifestyle choices will not only help prevent or reduce disease risk, but it will also give you an opportunity to enjoy the years of life available to each person.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read more here:
Mens Health Week 2020: Prostate cancer and other common health problems in Indian men; how to prevent them - Times Now

Recommendation and review posted by Bethany Smith

Lately, there has been rising awareness among people regarding the therapeutic potential of stem cells for disease management. This is one of the key factors contributing to growth of the global stem cell therapy market.

Further, identification of new stem cell lines, research and development of genome based cell analysis techniques, and investment inflow for processing and banking of stem cell are some of the significant factors augmenting expansion rate of the global stem cell therapy market.

Meanwhile, limitations associated with traditional organ transplantation such as immunosuppression risk, infection risk, and low acceptance rate of organ by body are few features leading to adoption of stem cell therapy. Moreover, high dependency on organ donors for organ transplantation is paving opportunities for growth of the stem cell therapy.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787

Moreover, expanding pipeline and development of drugs for new applications are driving growth of the global stem cells market. Growing research activities focused on augmenting the application array of stem cell will also widen the horizon of stem cell market. Researchers are consistently trying to develop novel methods for creating human stem cell in order to comply with the rising demand for stem cell production to be used for disease management.

Development of Advanced Treatment Method Augmenting Market Growth

Lately, various new studies, development of novel therapies, and research projects have come into light in the global stem cell therapy market. Some of these treatment have been by approved by regulatory bodies, while others are still in pipeline for approval of the treatment.

In March 2017, Belgian based biotech firm TiGenix has announced that its latest development- cardiac cell therapy AlloCSC-01 has reached in its phase I/II successfully. It has shown positive results. Meanwhile, the U.S. FDA has also approved the treatment method. If this therapy is well-accepted among the patients, then approximately 1.9 million AMI patients could be treated using the therapy.

Likewise, another significant development that has been witnessed is development novel stem cell based technology for treatment of multiple sclerosis (MS) and similar concerns associated with nervous system. The treatment is developed by Israel-based Kadimastem Ltd. Also, the Latest development has been granted a patent by reputed regulatory body.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=1787&ltype=S

Some of the prominent companies operating in the global stem cell therapy landscape are Anterogen Co. Ltd., RTI Surgical, Osiris Therapeutics Inc., Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co. Ltd., MEDIPOST Co. Ltd., Pharmicell Co. Ltd., and NuVasive Inc.

Some of these firms are following various growth strategies such as mergers and acquisitions, strategic alliances, and collaborations, and product development in order to strengthen their foothold in the global market for stem cell therapy.

Dermatology Segment Holds Prominence in Stem Cell Therapy Market

Stem cell therapy, primarily is a regenerative medicine. It encourages the reparative response of damaged, dysfunctional, or diseases tissue with the help of stem cells and associated derivatives. The treatment method is replacing the conventional transplant methods.

Stem cell therapy method has wide array of application in the field of nervous system treatment, dermatology, bone marrow transplant, multiple sclerosis, osteoarthritis, hearing loss treatment, cerebral palsy, and heart failure. The method aids patients fight leukemia and similar blood related diseases.

Among all, dermatology segment is leading in the global stem cell therapy market. The segment is substantially contributing to growth of the market. Stem cell therapy reduces the after effects of general treatment for burns such as adhesion, infections, and scars among others.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1787

Meanwhile, rising number of patient suffering from diabetes and increase in trauma surgery cases are anticipated to accelerate the adoption of stem cell therapy in the dermatology segment.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:TMR Research,3739 Balboa St # 1097,San Francisco, CA 94121United StatesTel: +1-415-520-1050Visit Site: https://www.tmrresearch.com/

See more here:
Stem Cell Therapy Market Grows on Back of Growing Awareness Regarding Regenerative Treatment Methods - BioSpace

Recommendation and review posted by Bethany Smith

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continued here:
Stem Cell Therapy Market to Incur Rapid Extension During 2025 - Owned

Recommendation and review posted by Bethany Smith

With a full devotion and dedication this superior GLOBAL HUMAN EMBRYONIC STEM CELL MARKET report is presented to the clients that extend their reach to success. Market parameters covered in this advertising report can be listed as market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. Each parameter included in this GLOBAL HUMAN EMBRYONIC STEM CELL MARKET business research report is again explored deeply for the better and actionable market insights. Geographical scope of the products is also carried out comprehensively for the major global areas which helps define strategies for the product distribution in those areas.

TheGlobal Human Embryonic Stem Cell Marketstudy with 100+ market data Tables, Pie Chat, Graphs & Figures is now released by Data Bridge Market Research. The report presents a complete assessment of the Market covering future trend, current growth factors, attentive opinions, facts, and industry validated market data forecast till 2026. Delivering the key insights pertaining to this industry, the report provides an in-depth analysis of the latest trends, present and future business scenario, market size and share ofMajor Players such as Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc and amny More

Global human embryonic stem cell market estimated to register a healthy CAGR of 10.5% in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the increase in tissue engineering process.

Avail 20% Discount on Buying This Report: Get a Free Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-embryonic-stem-cell-market

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global Human Embryonic Stem Cell Market By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), End User (Research, Clinical Trials, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Global Human Embryonic Stem Cell Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the Human Embryonic Stem Cell Industry

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-human-embryonic-stem-cell-market

The titled segments and sub-section of the market are illuminated below:

By Type

By Application

By End User

Top Players in the Market are:

Some of the major companies functioning in global human embryonic stem cell market are Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc, Waisman Biomanufacturing, Caladrius, Pfizer Inc., Thermo Fisher Scientific, Merck KGaA, Novo Nordisk A/S, Johnson & Johnson Services, Inc and SA Biosciences Corporation among others.

How will the report help new companies to plan their investments in the Human Embryonic Stem Cell market?

The Human Embryonic Stem Cell market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies of.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Human Embryonic Stem Cell Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: Human Embryonic Stem Cell Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

View original post here:
GLOBAL HUMAN EMBRYONIC STEM CELL MARKET Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth, Business...

Recommendation and review posted by Bethany Smith

Cardiac rhythm management refers to a process of monitoring functioning of the heart through devices. Cardiac rhythm management devices are used to provide therapeutic solutions to patients suffering from cardiac disorders such as cardiac arrhythmias, heart failure, and cardiac arrests. Cardiac disorders lead to irregular heartbeat. Technological advancements and rise in the number of deaths due to increasing incidences of heart diseases and increasing aging population are some of the major factors driving the cardiac rhythm management market. Heart disease is one of the primary causes of death in the U. S. Excess of alcohol consumption; smoking, high cholesterol levels, and obesity are some of the major causes of heart diseases. Cardiac rhythm management is conducted through two major devices: implantable cardiac rhythm devices and pacemakers. Implantable cardiac rhythm devices treat patients with an improper heartbeat. Based on the device, the cardiac rhythm management market can be segmented into defibrillators, pacemakers, cardiac resynchronization therapy devices, implantable defibrillators, and external defibrillators. Pacemakers are used to treat patients with a slow heartbeat. Based on the end user, the cardiac rhythm management market can be segmented into hospitals, home/ambulatory, and others.

North America has the largest market for cardiac rhythm management due to improved healthcare infrastructure, government initiatives, rise in incidences of cardiac disorders, growing number of deaths due to cardiovascular diseases,and increasing healthcare expenditure in the region. The North America market for cardiac rhythm management is followed by Europe. Asia is expected to witness high growth rate in the cardiac rhythm management market in the next few years due to increasing incidences of cardiovascular diseases, growing disposable income, rise in awareness regarding heart disorders and relevant treatments, and improving healthcare infrastructure in the region.

For detailed insights on enhancing your product footprint, request for a Sample here @https://www.persistencemarketresearch.com/samples/3868

Increasing the prevalence of cardiovascular diseases, technological advancements, rise in life expectancy, increasing awareness regarding cardiac disorders, and government initiatives are some of the major factors that are expected to drive the market for cardiac rhythm management. In addition, factors such as a rise in disposable income, increasing aging population, and high cost associated with heart disease treatment are expected to drive the market for cardiac rhythm management. However, economic downturn, reimbursement issues, the importance of biologics and stem cells, and inappropriate use of the devices are some of the factors restraining the growth of the global cardiac rhythm management market.

Growing population and economies in the developing countries such as India and China are expected to drive the growth of the cardiac rhythm management market in Asia. In addition,factors such as innovations along with technological advancements such as miniaturization, introduction of MRI pacemakers, biocompatible materials and durable batteries, and continuous rise in aging population and increasing cardiovascular diseases such as arrhythmias, stroke, and high blood pressure are expected to create new opportunities for the global cardiac rhythm management market. An increasing number of mergers and acquisitions, rise in the number of collaborations and partnerships, and new product launches are some of the latest trends in the global cardiac rhythm management market.

To receive extensive list of important regions, ask for TOC here @https://www.persistencemarketresearch.com/toc/3868

Some of the major companies operating in the global cardiac rhythm management market areMedtronic, Abbott Laboratories, Boston Scientific, St. Jude Medical, Altera, and Sorin.Other companies with significant presence in the global cardiac rhythm management market include

Read more:
Cardiac Rhythm Management Market to Witness Rapid Increase in Consumption During 2015 2021 - The Canton Independent Sentinel

Recommendation and review posted by Bethany Smith

The novel coronavirus that emerged in late 2019 (officially known as SARS-CoV-2) raises new concerns for people living with cancer, ranging from worry about whether youre at higher risk to the prospect of delayed cancer treatment.

COVID-19, the respiratory disease caused by the new coronavirus, is mild to moderate in about 80% of cases. Symptoms may include fever, cough, shortness of breath, chills, muscle pain, headache, sore throat and new loss of taste or smell. However, some people have no symptoms at all. About one in five people will develop severe disease that may progress to pneumonia and respiratory failure.

While anyone can contract the coronavirus, certain individuals are at greater risk for severe disease, namely people over age 60, those with compromised immune systems and people with underlying health conditions, such as chronic lung disease, heart disease, diabetes or high blood pressure. Some studies have found that people living with cancer may be more likely to become seriously ill.

Some chemotherapy drugs can cause a low white blood cell count (neutropenia), a temporary immune suppression that makes you more susceptible to infections. People who receive bone marrow transplants or CAR-T therapy are especially susceptible. Hormone therapy and checkpoint inhibitors, however, do not appear to increase the risk.

The pandemic may affect your treatment because hospitals are short on staff and supplies, and infection risk is higher in medical settings. Some care providers are relying more on telemedicine. If you have scheduled surgery, infusions or scans, you may experience delays, depending on the stage of your cancer. In some cases, it may be possible to receive treatment at home. If you are in a clinical trial, follow the guidance of the research staff. Most people at average risk for cancer can safely delay routine screenings, such as mammograms.

Maintain good communication with your care team to discuss the best options. If you do need to receive treatment or scans at a medical facility, the staff may employ extra safety measures.

Everyone should take precautions to prevent COVID-19, but these are especially important for people at higher risk. A new type of test can show who has developed antibodies, but it is not yet clear whether these offer protection against the coronavirus, or, if so, how long such immunity might last. Prevention measures include staying away from people who are sickand avoiding others if you are illwashing your hands thoroughly, using hand sanitizer, wearing a face mask and not touching your mouth, nose or eyes. Get your annual flu shot, and ask about a vaccine to prevent pneumonia.

Social distancing will remain important even after local stay-at-home orders have been relaxed. Avoid crowds, work from home if you can and stay at least six feet away from people you dont live with.

If you have mild symptoms, you can often manage them at home by drinking plenty of fluids and using over-the-counter fever, cough and pain medications. But check with your care team to see whether these might interfere with your cancer treatment. Get further care if you have trouble breathing. Call ahead before you go to a clinic or hospital.

Currently, no medications are approved for the treatment of COVID-19, but hundreds of studies are underway. Be cautious about rumors and overly optimistic information about treatments that have not been tested in randomized clinical trials.

Many coronavirus vaccine trials are also ongoing. Experts predict a vaccine could be available by the end of 2021.

Go here to read the rest:
COVID-19 and Cancer - Cancer Health Treatment News

Recommendation and review posted by Bethany Smith

Adenomyosis Treatment Market Industry Forecast To 2026

Garner Insights has titled a new research report named as Adenomyosis Treatment Market 2020 to its consistently extending database. The report clarifies this through a series of channels which include data ranging from rudimentary data to an undeniable estimate. It consolidates all the fundamental factors that are foreseen to change inside the market. The information would thus be used to heighten an organizations standing in the worldwide market.

The novel COVID-19 pandemic has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. This report presented by Garner Insights contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak.

Get a Sample Report @:https://www.garnerinsights.com/Global-Adenomyosis-Treatment-Market-Size-Status-and-Forecast-2020-2026#request-sample

Major Manufacturer Detail: Bayer AG, Ferring B.V, Johnson & Johnson, Novartis, Merck, Pfizer, Contura

The Important Type Coverage:Anti-inflammatory drugs, Hormone medications, Other

Segment by ApplicationsHospital, Clinic, Others

The Adenomyosis Treatment report consists of streamlined financial data obtained from various research sources to provide specific and trustworthy analysis. Evaluation of the key market trends with a positive impact on the market over the following couple of years, including an in-depth analysis of the market segmentation, comprising of sub-markets, on a regional and global basis. The report also provides a detailed outlook of the Adenomyosis Treatment market share along with strategic recommendations, on the basis of emerging segments.

Enquire Here For Discount Or Report @https://www.garnerinsights.com/Global-Adenomyosis-Treatment-Market-Size-Status-and-Forecast-2020-2026#discount

Some Of The Major Geographies Included In This Study:

North America (U.S and Canada and Rest of North America)Europe (Germany, France, Italy and Rest of Europe)Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)

Some major points covered in this Adenomyosis Treatment Market report:

1. An overall outlook of the market that helps in picking up essential data.2. The market has been segmented on the basis of the product types, applications, end-users, as well as the industry verticals, in light of numerous factors. Considering the market segmentation, further analysis has been carried out in an effective manner. For better understanding and a thorough analysis of the market, the key segments have further been partitioned into sub-segments.3. In the next section, factors responsible for the growth of the market have been included. This data has been collected from the primary and secondary sources and has been approved by the industry specialists. It helps in understanding the key market segments and their future trends.4. The report also includes the study of the latest developments and the profiles of major industry players.5. The Adenomyosis Treatment market research report also presents an eight-year forecast on the basis of how the market is predicted to grow.

View Full Report @ https://garnerinsights.com/Global-Adenomyosis-Treatment-Market-Size-Status-and-Forecast-2020-2026

About Us:Garner Insights is a Market Intelligence and consulting firm with an all-inclusive experience and vast knowledge of the market research industry.Our vast storage of research reports across various categories, gives you a complete view of the ever changing and developing trends and current topics worldwide. Our constant endeavor is to keep on improving our storage information by providing rich market reports and constantly improving them.

Contact Us:Mr. Kevin Thomas+1 513 549 5911 (US)+44 203 318 2846 (UK)Email: sales@garnerinsights.com

Original post:
Impact of Covid-19 on Adenomyosis Treatment market [ PDF ] 2020 | TOP BUSINESS GROWING STRATEGIES, TECHNOLOGICAL INNOVATION AND EMERGING TRENDS OF...

Recommendation and review posted by Bethany Smith

As a mother who is open about having a transgender teen, Ive heard it all: everything from how abusive it is to enable a confused child to how Im condoning children as young as five getting genital surgery.

These ideas are as absurd as they are inaccurate. Sadly, that doesnt make them uncommon. Inside of a year, Ill receive hundreds, if not thousands, of comments like these on social media and in email. People have plenty of opinions about what affirming a trans child means, but what they often lack are facts.

This mother is honouring inclusion at home, in an effort to raise young advocates read it here.

Trans people are regularly attacked, both verbally and physically, for simply existing in the world. They are, by far, one of the most misunderstood and mistreated demographics on the planet. Trans youth often face this hatred as well, along with having their maturity and sense of self questioned by everyone from family to physicians. Many think theyre too young to know who they are or are not and cant possibly make decisions that could impact their future.

Their accepting parents, by default, become targets of these ideas, too. For example, how dare we feed into our childrens fantasies? What if little Timmy wanted to become a dog or a superhero? Would we allow that, too?

"Trans people are regularly attacked, both verbally and physically, for simply existing in the world."

Sigh.

As someone who wouldnt have to write for a living if she could pay the bills with misdirected hate from strangers, lets look at some of the biggest misconceptions about transgender kids.

Trans and non-binary children are anything but confused. A recent studyfound that theyre just as sure of who they are as kids who are cisgender (those who identify with the gender assigned at birth).

Gender identity is something we all have its just that most of us dont have to think about it because the world has always seen us the way we see ourselves. Trans kids do have to think about and often talk about gender because who the world has perceived them as isnt who they are.

If theyre lucky, theyll find willing ears and open hearts to listen.

Not quite. People often conflate gender identity and gender expression. Gender identity is who we are, and gender expression is how we express that.

There are many boys who wear dresses and still identify as boys. This is known as gender non-conforming, which means they dont conform to the societal norms expected of their gender.

"Trans kids do have to think about and often talk about gender because who the world has perceived them as isnt who they are."

Gender identity runs deeper than what we wear or what activities we participate in.

It should also be noted that gender identity is not the same as sexual orientation. There are many gay, lesbian, bisexual, pansexual and asexual trans people.

Horrifically, this was tried for years, and falls under the same category as trying to convince gay people theyre straight. Conversion therapy also known as reparative therapy has been banned in many places because of the damage it does to the individual.

A quick look at the statistics shows a high risk of trauma, mental health issues and self-destructive behaviours. Trying to force people to be who theyre not is extremely harmful.

Today, we know its better to help kids be who they are, not who we expect them to be. Outcomes for children who are affirmed in their gender identity are very positive. In fact, a study by Trans PULSE showed that trans youth who receive strong parental support see their risk of suicide and self-harm decrease approximately eight-fold, to a level that is nearly on par with their cisgender counterparts.

Queer parents with young kids sometimes have to navigate learned heteronormative attitudes read about that here.

If anything, its not easy enough. When a young trans person wants access to transition-related medical care, the process is long and often daunting. Wait lists can span months or even years, followed by several appointments and assessments between each step. Historically, medical transition has been difficult to access and heavily gatekept, especially for minors. Things are slowly getting better as more professionals learn how to best support their trans patients, but it is by no means an easy or fast process.

I promise you this isnt happening. When younger children come out as trans, they will often socially transition, which means living as the gender they identify as, and sometimes using a new name and/or pronouns. They might be followed by a gender specialist or clinic, but there are no affirming medical supports for pre-pubescent trans youth.

Hormone blockers a group of safe, reversible medications with a long history of pediatric use block unwanted puberty from continuing, if thats needed. Hormone treatment and some gender affirming surgeries are reserved for teens and older, while other surgeries are only performed on adults. The ages vary depending on individual cases, medical standards and geographic location, but it is certainly not something young children have access to. Its also important to note that not all trans or non-binary people medically transition, and that medical transition itself is very individual.

"Ask a parent of a trans kid what it feels like when they no longer hear their child crying in the shower ...."

As always, when it comes to something we dont have personal experience with, its best to get our information from the source. Rather than reading Uncle Jerrys late-night Facebook post about the dangers of puberty blockers, go find a trans persons book, blog or YouTube channel discussing how life-saving these medical supports can be. Ask a pediatric endocrinologist working in a gender clinic about how many trans kids change their minds about transition (spoiler: usually less than 1 per cent). Ask a parent of a trans kid what it feels like when they no longer hear their child crying in the shower, and instead see them living a full and happy life (I speak from experience on that one).

Research before you judge. Kids like mine will be all the better for it.

See the original post:
I Am A Mother of a Trans Teen and Heres What Youre Getting Wrong about Them - CBC.ca

Recommendation and review posted by Bethany Smith

I've stayed up all night maybe twice in my life my 27th birthday, and when I got really into binge-watching "Shameless" as a teenager. But I tried it again to follow what I've coined the "YouTuber sleep schedule" and see whether a late-night way of life really inspires the imagination.

Studies have shown how night owls are often more creative than early birds. But most of us don't live in a world where our social and work schedule fits around our body clock, so we have to make do with being a bit groggy some of the time.

YouTubers don't really have to worry about this, and often when watching their videos, I'll hear the creator say they are recording at 4 a.m., or they might cut to their future selves editing really late at night or early in the morning. Tana Mongeau, for example, is notorious for her late nights and later starts, and has been known to sleep through important business meetings and even her best friend's surgery.

This made me start questioning why YouTubers seem to have abysmal sleep schedules, and what benefit, if any, this habitual late night cycle has for their careers.

YouTuber Garrett Watts told Insider he's struggled with his sleep as long as he can remember. He references his lack of routine often on his channel, including one vlogging project where he attempted to get up at 5 a.m. every day.

"I've always had this weird theory about my family, like were my ancestors weird cave protectors that had to keep watch at night?" he said. "I have no idea why I'm so nocturnal. But something that you're going to find time, and time, and time, and time again with creatives is the nocturnal sleep schedule thing."

Garrett Watts tried to kickstart his sleep schedule. Garrett Watts / YouTube

Commentary YouTuber Kavos told Insider he also has the "worst sleeping pattern imaginable."

"I wake up at 9:30 p.m. and stay up until like 1 p.m. the next day," he said. "Then go back to sleep until 8/9 ... Or, like yesterday, I just didn't sleep."

He said he's definitely a night owl, but his schedule started getting a bit out of control when he stayed up until 9 a.m. one night to finish a load of work and it just hasn't recovered since.

One aspect that doesn't help is the fact Kavos lives in the UK and the majority of his audience is American. Being a commentary YouTuber, he has to be "on the ball" to cover the latest trending topics. Being his own boss helps him dictate whether he just doesn't sleep one night because he wants to keep up to date with everything that's going on.

"I'm naturally up later because my audience is and that's when a lot of drama goes down," he said. "I can't complain really because I used to stay up before I did this for a career anyway."

I'm also a night owl. I struggle with early starts and I'm much more productive after midday. Even so, it was clear I don't have the stamina that I used to when attempting this schedule for myself one recent Friday evening.

I knew I had nothing to do on Saturday thanks to the coronavirus, so it felt like a good day to stay up as late as possible without too much damage being done by sleeping in the next morning. But I struggled to stay up much later than 2 a.m. after a full workday.

Tana Mongeau is notorious for her poor sleep schedule. MTV

I had a late interview at 8 p.m. and definitely felt a surge of energy to get things done afterwards. I even got a burst of creativity at around 10 p.m. and wrote down some copy that had been rattling round in my head, then fired off some emails to sources and contacts on the West Coast who normally wouldn't hear from me until the morning.

I probably won't make a habit of working late, especially as the lines between work and home life are already so blurred at the moment. But I can certainly see the attraction the quiet transquility makes it much easier to find that intense concentration I'm always chasing.

Watts said he often prefers to work at night because there are fewer distractions. Sometimes he tries to sit down and edit during the day and it's just "a lost cause" because he can't get into the zone.

"There's something to be said for the creativity that thrives at nighttime when the rest of the world is down," he said. "That flow state, that hyper-focused mode as they call it, that any musician or artist or anyone who makes anything will tell you about, I think that's much easier to tap into at night when all distractions are gone."

Psychologist Perpetua Neo told Insider in a previous article that creatives can often feel that "everything becomes beautiful at night."

"It can be beautiful in a melancholic way," she said. "And creatives tend to draw this melancholy and reflectiveness as a source of inspiration."

Filmmaker and YouTuber David Lehre has always had a night owl schedule as well, staying up until 3 or 4 a.m. then taking naps during the day. He told Insider he feels better working at night because nobody talks to him, calls him, or emails him, and he can really absorb himself in a project.

"I do feel a different vibe at night," he said. "I feel like the world settles down and I can just hone in on what I'm working on."

He said one person had a theory that it's because there's less energy being projected into the world around you at that time.

"If there's people walking around, there's people talking, there's cars driving around, all those things give off energy," he said. "And at night time when nobody's walking around, no cars are driving, and there isn't this energy percolating around, it kind of allows you to focus in."

The quiet means he can dedicate his full attention to craft whatever he's making, with a different ability for processing things in his mind.

"You can go with the flow with the creativity and there's no boundaries with hours or time," he said. "It's just, this is what I want to make, and I'm going to make it whenever it strikes me."

Sometimes creativity is fueled by the night. Crystal Cox/Insider

Dr Nerina Ramlakhan has been helping people improve their sleep for 25 years. She told Insider that sometimes people give themselves this label of "night owl" when actually they've formed patterns of behavior that build and train a night owl physiology delaying their release of the sleep hormone melatonin with blue light from electronic devices, and oversleeping in the morning, for example.

"If you stay up late, and you oversleep in the morning, that creates a kind of hangover called sleep inertia, which means that you're less inclined to eat breakfast because you don't have an appetite," Ramlakhan told Insider. "This starts to lower the metabolism because you're not eating until later, and you shift the whole circadian rhythm forward."

The problem with burning the midnight oil is that each sleep phase plays a role in our physiology. Sleep before 12 a.m., for instance, is really important for energy, metabolism, and re-balancing the thyroid. Sleep experts also have a theory that there is a period in the night which is where our brain does most of its regenerative work and clears out all the junk it has accumulated over the day.

"People who are suffer from metabolic disorders, adrenal exhaustion or chronic fatigue, it's really important they are getting those early phases of sleep," said Ramlakhan. "But ironically, it's often the people who are going to bed too late who have got those things, and they find it difficult to break the pattern."

She said people often only seek help with their sleep if they completely burn out and break down because of it. Many of the creators Insider spoke to said they didn't feel any negative impacts on their health because of their schedules, but Ramlakhan said this may just be because they haven't "suffered enough yet."

Over the ten years she was working at a psychiatric clinic, she saw people with depression, anxiety, and addictions who had been messing around with their sleeping patterns so much they were running themselves into exhaustion.

Without sleep, you cannot exercise effectively, if at all, and you're more likely to make less healthy choices about your lifestyle and diet living off sugary foods, caffeine, and even drugs to increase your energy during the day and pills or alcohol to help knock you out at night.

There's also a tendency to start withdrawing and isolating yourself if you're staying up beyond when everyone else has gone to bed and asleep when everyone else is awake.

"Sleep is a reflection of everything of the way we live, and the way we've lived, and everything that goes on in our lives," Ramlakhan said. "The body and the nervous system keep the score."

Ramlakhan said she thinks it's a bit of a myth that all creatives are night owls, but there is a benefit to working late at night many people could take advantage of regardless of their chronotype. When she is on a book deadline, she often wakes up about 3 a.m. and gets some writing done because it's such a tranquil time of night.

"We all naturally wake up between 2 and 4 in the morning," she said. "If you look at the structure of our sleep, human beings are designed to be biphasic ... So there is some flexibility built into the design of our sleep. We've all got different routines and rhythms and it really is about finding your innate rhythm."

She has written five non-negotiables for getting better sleep in her role as a sleep expert for Silentnight. They are eating breakfast first thing in the morning, limiting caffeine intake, drinking plenty of water, getting into bed earlier, and keeping electronic devices out of the bedroom.

Sleep should improve after 7 to 10 days of doing these things, she said, and after that, you can start experimenting a bit.

Watts said he's working on splitting the difference, because he still wants to be nocturnal to some degree while also being a "functional human being" and interacting with the world when it's awake. He's started a plan during lockdown of making sure he wakes up before 11 a.m. every day.

"I need to work on that kind of still being a night owl but still being part of my world too," he said. "And I think I can do that because come on, waking up at 11? Those standards are like pretty low enough to where I think I can reach them."

For other creators like Kavos, a late schedule will probably just always be part of the way he works. In order for some creators to continue to be as successful as they are, something's gotta give, and often, that's a bedtime.

"I have sacrificed many bedtimes," he said. "It's just part of the job."

Read more:

Creativity and depression don't go hand in hand, but it can seem like they do here's why

Garrett Watts might be the most unpredictable creator on YouTube, and that's why fans live for his rare uploads

Why some YouTubers are destined to become supervillains

YouTubers are calling out the platform's 'cancel culture' that subjects them to a rampant hate mob and sees them lose thousands of subscribers in a matter of hours

The struggle YouTubers are facing with their body image isn't just a result of vanity. It's a long-standing battle between hate comments, constant comparisons, and self-compassion.

Read this article:
I tried the YouTuber sleep schedule, and it's not sustainable longterm - Insider - INSIDER

Recommendation and review posted by Bethany Smith

J.K. Rowling, author of the beloved "Harry Potter" series, published a lengthy blog post on her website this week, attempting to explain her controversial tweets about transgender women.

The author has been widely criticized for a history of making transphobic comments, including most recently writing on Twitter that trans activism was harming women, and reiterating her rejection of the existence of non-binary and intersex people.

Rowling said in her post that one of the reasons she's taken such positions is that she's "concerned about the huge explosion in young women wishing to transition," as well as the growing number who she says seem to be detransitioning, or returning to the sex they were assigned at birth.

They do so, Rowling wrote, "because they regret taking steps that have, in some cases, altered their bodies irrevocably, and taken away their fertility."

She added: "Some say they decided to transition after realizing they were same-sex attracted, and that transitioning was partly driven by homophobia, either in society or in their families."

Rowling also said that 10 years ago most people who wanted to transition were assigned male at birth, but now the UK "has experienced a 4,400% increase in girls being referred for transitioning treatment," adding that autistic girls are "hugely overrepresented."

Rowling's claims are not only unsupported by data, but perpetuate dangerous myths about trans people that can inhibit their access to life-saving care.

Demographers don't know exactly how many transgender people there are or how that number has changed, since there are a range of terms to describe transgender identities and population-based surveys have historically not asked about trans identities.

Rowling's 4,400% increase reference seems to come from a report finding that 40 people assigned female at birth in the UK sought gender treatment between 2009 and 2010, while 1,806 did between 2017 and 2018.

Polly Carmichael, a psychologist who heads The Tavistock and Portman mental health clinic's gender identity service (which was the only trans affirming service in the UK in 2016), told NBC that while she is seeing large increase in the number of patients in need of gender-affirming care, this is likely due to an increase in visibility for trans services and gender varience rather than a "trend."

"Young people experiencing gender dysphoria is a real phenomenon," Carmichael said. "It can be incredibly isolating. If you don't feel you belong in a particular category that you've been assigned to. Many adolescents do become very distressed and self-harm."

Rowling's assertion that being a trans boy or man is suddenly more common than being a trans girl or woman is also questionable. In fact, one 2019 survey from the UK government found 3.5% of the population were trans women (women who were assigned male at birth) while 2.9% were trans men (men who'd been assigned female at birth).

In this Aug. 23, 2007 file photo, a sign marks the entrance to a gender neutral restroom at the University of Vermont in Burlington, Vt. AP Photo/Toby Talbot, File

While more people who were assigned female at birth have transitioned in recent years, that's likely because gender-affirming treatments such as hormone replacement therapy (HRT) and surgeries weren't that accessible to transgender people until recently.

Insurance companies refused to cover gender-affirming care for decades and many primary-care physicians were unwilling to provide HRT, a medication also prescribed for menopause, to transgender and nonbinary patients because medical guidelines had not changed to include them.

It wasn't until 2017 that "gender identity disorder" was decategorized as a mental disorder in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders. In fact the World Health Organization removed "transsexualism" from the International Classification of Diseases only in 2018 a move that, the WHO said, would allow for better "access to necessary health interventions."

Many trans people simply have more access.

While detransitioning does happen, it's very rare, with one analysis showing that less than a percent of 3,398 trans people said they'd experienced transitioned-related regret, or had detransitioned.

And contrary to Rowling's assertion that detransitioning means the person regretted transitioning, "the most common reason for detransition is the person couldn't cope with the family and community support they lost and the experiences of transphobia," according to the UK organization Stonewall.

Others may be unable to find a job or housing, or no longer identify the gender they transitioned to feel more valid in.

Research actually shows any feelings of regret are typically related to unsatisfactory surgical results.

Getty/Angela Weiss

These fears about detransitioning can be dangerous because they invalidate the gender identities of young trans people and make it more difficult to obtain access to care.

Across the United States, state representatives are attempting to pass legislation that would go against medical guidelines and ban doctors from providing gender-affirming treatments to transgender youth. Their arguments are based on the same logic of Rowling's assertion that transgender youth are simply going through a phase they will grow out of.

Studies have debunked this idea and shown children as young as four develop their gender in the same ways as their cisgender peers.

In a study released in 2019, researchers found no significant differences between the trans and cis kids' gender development, or how they grew to understand and formulate their gender.The findings also revealed that transgender children gravitate toward the same gendered toys, clothing items, and friends as cisgender participants, regardless of how long they had been socially transitioned.

"Gender-affirming health care saves lives," Shawn Meerkamper and Dale Melchert, senior staff attorney and staff attorney for the Transgender Law Center, told Insider for a previous story.

Frank Franklin II/Associated Press

In her essay, Rowling made the point that the gender dysphoria when a person feels as if their body doesn't match their gender identity that many young trans people are feeling is a "social contagion."

She cited a 2018 study from Brown University that argued the "rapid-onset gender dysphoria" (ROGD), typically for those assigned female at birth, came out of social pressures from peers rather than genuine feelings of being transgender.

This study has since been cited by media outlets and gender-critical feminists as an argument against transgender youth receiving gender-affirming care. Like Rowling, people have used this research to make the argument that being trans is a trend.

However, another recent study from Brown University debunked the claim that ROGD exists.

Arjee Restar, a transgender researcher at Brown, wrote a critique of the study that found themethodology including surveying parents of trans teens who had read anti-trans websites is flawed and pathologizes trans people.

PLOS One, the journal the 2018 study appeared in, published a revised version that said the data was based on observations of parents rather than data from the trans teens themselves. If a parent does not see their child's gender identity as valid, they are likely more susceptible to cite ROGD as the reason their child has started to openly identify as trans.

Restar told BuzzFeed News that the corrected version of the study was still flawed and "below scientific standards."

"It's important to use methods and terminologies that don't further stigmatize an already disenfranchised community," Restar said.

Read More:

Trans 'Harry Potter' fans say they are devastated by JK Rowling's transphobia but some say it's a distraction from the violence against trans Black people

'Transgender women are women': Daniel Radcliffe rebukes J.K. Rowling's comments and apologizes to 'Harry Potter' readers if their experience of the books is now tarnished

People are sharing hormones on Google Docs and turning to 'grey market' pharmacies to get gender-affirming care during the pandemic

Link:
JK Rowling falsely claims an 'explosion' of girls have de-transitioned - Insider - INSIDER

Recommendation and review posted by Bethany Smith

Twelve papers were included for analysis. All passed the CASP checklist (summary provided in supplementary table 1). Qualitative studies ranged from open, unstructured and semi structured interviews with 1660 participants. Six studies recruited women from community, and six recruited from attendance to clinical consultation (Table2). All studies used a described method of qualitative analysis, such as thematic coding (Table3).

We identified three key themes across all papers in the context of barriers to women accessing care for abnormal or heavy menstrual bleeding.

Health literacy is the ability to interpret, maintain, understand and use health information to make informative health decisions and follow treatment instructions.

Half of the included studies identified general health literacy as a barrier to accessing care for AUB [12, 15, 19, 21,22,23]. One American study in 2010 noted the variability in 71 women in the perception of heavy and irregular bleeding [19]. Women described heavy bleeding by the number of pads used, the quality of the bleeding, and the length of bleeding [19]. The perception of blood loss was also described to be affected by the types of sanitary protection used [12]. Women found identification of normal challenging, and if experienced for long enough, heavy or excessive bleeding became normalised and did not warrant the trouble of medical investigation. This was true in the Chicago study where the most commonly cited reason for delayed fibroid diagnosis was the perception that heavy bleeding was normal [21]. A United Kingdom study of 21 women found that explanations of heavy bleeding were varied, including the appearance of blood and how it felt. In this study, women commented how it was difficult to describe experiences, particularly to someone who did not have similar feelings [13]. Only four women in this study had open discussions about periods with family or friends. In another study, even though women described discussing the menstrual experience with others, heaviness of blood loss was not often brought up [17].

A study of Pasifika womens knowledge and awareness of gynaecological cancer in New Zealand found that there was a need for culturally appropriate, easily accessible and correct information [23]. Many women in this study had never heard of the term gynaecology as there is no literal Tongan or Samoan translation of the word [23]. Women were aware of gynaecological cancers through personal experiences and relatives or friends that were diagnosed. This is re-iterated in another New Zealand study in womens experiences with gynaecological support services where women expressed need for appropriate and timely information [18], and a United Kingdom study where half of the women who were diagnosed with uterine fibroids had never previously heard of the condition and expressed frustration they that lacked this knowledge [21].

Some women who developed their understanding of gynaecological conditions from family often had a confused interpretation of their symptoms. For example, in a United Kingdom study [20], many women believed gynaecological cancer symptoms such as abdominal size and irregular periods were due to factors such as diet, and managed themselves through avoiding certain foods:

Id probably try and sort myself out first with eating and say right, thats enough of dairy

In the same study, one woman disclosed that twins ran in her family, and that her heaviness and period pain was caused by release of two eggs during ovulation:

My nan reckons that a double egg comes from one side thats why I have been told that I get those pains [20].

In a study of women previously diagnosed and treated for endometrial cancer [22], general uterine health and Pap smears were confused. Many women were upset that their routine cervical smear did not pick up EC:

It disappointed me as long as you go for a smear test your fine [22]

This was echoed in a UK study, where eight of eleven women had considered AUB as a risk of cancer, but reassured themselves that a normal smear meant this was not the cause [13]. Whilst most women were aware of the need for routine Pap smears, confusion meant that women did not receive or perceive the correct information.

Gynaecological health has historically remained a taboo subject, yet this stigmatisation has meant that many women today are not able to openly talk about issues such as menstruation. This has resulted in many women normalising symptoms or suffering in silence.

Women may seek advice from friends to find reasons for normalisation and/or because they feel embarrassed or ashamed. For example, one woman noted:

I couldnt talk to my mum because straight away shed say to me you have to go to the hospital [22]

Years of experience with menstrual cycles meant that for some women, change in vaginal discharge or spotting was no cause for alarm, especially when these symptoms varied from day to day. Over half of women with uterine fibroids minimised symptoms, by suck (ing) it up and dealing with it [21]. Some women attributed their heavy periods to natural events, and assumed they were unlucky in having bad flow [13]:

Theres not a lot of point in reading or listening to anything, because it cant be changed [13]

Women seemed to prioritise uterine/vaginal health lower than most other health issues, and ignored significant changes:

After I got out of bed the next morning it had eased off [22].

It doesnt happen the next day so you get on with your life [22]

Women were worried to seek medical consultation as they thought they would be wasting their time:

You tend to think you are wasting their time. You are not too sure whether it is happening to everybody [12]

For those with excessive heavy bleeding, social embarrassment is a major determinant for discussing these issues, as many women provided examples of staining their clothes in public [19]. These experiences resulted in fear of social activities and avoidance of situations in which they felt stranded. For some, fear of leakage due to irregular timing and difficulties of management was a factor for women seeking seek consultation, particularly if these were increasing (which also shows how much women tolerated before they would seek help) [16, 20]. Yet for others, this held them back from seeking care:

I cancelled my doctors appointments for that reason, cause I bleed through everything. Im afraid of sitting there and going through my clothes [19]

For women who identify as Pasifika, embarrassment of revealing private parts during medical investigation was a big deterrent [23]. Many women felt uncomfortable with showing personal body parts, and find gynaecological examinations (pelvic exam) painful and scary:

I dont even like seeing myself thats a huge barrier as to why I find it tricky accessing the doctor for smears or gynaecology troubles [23]

you know they may perform a test that hurts are very scary-if I can avoid it, I do [23]

Primary health care providers such as General Practitioners (GPs) are often the first medical point of contact for women with AUB. Therefore GPs have an important responsibility to take a thorough history and listen to all concerns to provide coordinated care with specialists when needed.

Most studies highlighted communication with health professionals as a key barrier to AUB investigation. Firstly, a regular or long term health care provider were viewed as preferential as these doctors know medical and family history [15, 22, 23]. Having an established and trusting relationship with a GP was found to be a positive facilitating factor for all women:

I have been with my GP for years and he knows what has happened to me I just trust him [23]

Many women felt they could not speak to a male doctor about anything related to uterine health, and almost all women preferred to see a female doctor [20, 22, 23].

Surprisingly, eight of the 12 studies all identified normalisation and dismissal of womens concerns by the health practitioner as an important barrier to accessing appropriate care [12,13,14,15, 17, 20,21,22] and was an issue that ran through studies from 1999 to 2017. In interviews with women 612months post endometrial cancer surgery, a participant noted her symptoms were brushed off as a cause of menopause [22]. This attitude lead to women feeling reluctant to complain about symptoms, and didnt want to bother GPs about their problems [17, 20]. In another, a womans period pain was dismissed, leading her to question the genuineness of her own experiences [14]. Women felt dissatisfied when doctors did not ask about how it was affecting their lives, their problem had not been given a name or had been explained vaguely, and felt that consultation had achieved little [13]. One woman found she had to fight for treatment as her prolonged and heavy bleeding was impacting her relationship with her husband:

The woman [doctor] said these are things women have to put up with. I dont think so. I wont sacrifice my sex life [16].

Two qualitative studies which were filtered in the selection criteria for this review were based on the perspective of health care providers. Supporting the challenges described, an American study found that of 417 GPs surveyed, 87% self-reported that they always ask a quality of life question (in relation to AUB) however only 17.5% ask a mood associated question. Only 18% of GPs thought that asking about quality of life was essential in evaluating women with AUB [25]. A United Kingdom study found that even GPs had difficulty in describing normal periods. Female GPs reported that they were likely to ask details such as how many pads or tampons were used during a patients cycle. However, male GPs were less likely to go into this detail [26].

Incorrect diagnosis or inappropriate treatment was also described by women. In one study [16], several women had been prescribed norethisterone, and oral hormone treatment for their symptoms. At the time of the study (2006) GPs were advised not to prescribe this drug as it had been shown to not be effective at reducing blood loss. Worryingly, in two other studies of gynaecological cancer, many participants were given clinically irrelevant treatment following initial consultation for AUB:

I went back and forth the doctors gave me tablets, nothing still wouldnt stop [22]

Youre just being silly, youre being paranoid [15]

My GP said I had an infection [15]

The doctor at the emergency said I had gastro [15]

The use of medical jargon by gynaecological specialists was noted in a number of studies, which left women feeling lost and fearful [15, 18, 22].

Logistics of attending appointments were often noted as barriers to seeking care, for example, long wait times, availability of doctors, and the demand of family, work and social commitments.

(GP) you ring now, you get an appointment in 3 weeks [22]

It would have to be easier to get an appointment with the GP. It really is that, that is such a bloody drama. [20]

I went to one she had a baby there was another doctor, then she left the clinic as well, then Ive got doctor L. Now hes only in every Wednesday [15]

It keeps moving down the list of priorities coz something else takes precedence. [20]

Follow this link:
Barriers to seeking consultation for abnormal uterine bleeding: systematic review of qualitative research - BMC Blogs Network

Recommendation and review posted by Bethany Smith

Dallas, Texas, June 15, 2020 (GLOBE NEWSWIRE) -- The Global Preimplantation Genetic Testing Market Size 2018, By Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism) Region and Forecast 2019 to 2025 study provides an elaborative view of historic, present and forecasted market estimates.

Request a pdf sample @https://www.adroitmarketresearch.com/contacts/request-sample/1483

Adroit Market Research report on global preimplantation genetic testing market gives a holistic view of the market from 2015 to 2025, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2015 to 2017, with the base year of estimation as 2018 and forecast from 2019 to 2025. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global preimplantation genetic testing market have been studied in detail.

The global preimplantation genetic testing market is projected to reach USD 1,147.9 million by 2025, growing at a CAGR of 11.8%. Increasing rate of infertility worldwide, growing number of fertility clinics across the globe, public-private investments in the field of preimplantation genetic testing, high risk of chromosomal abnormalities in the fetus with increasing maternal age and technological advancements in the field of genetic analysis are the factors driving the growth of the preimplantation genetic testing market.

Browse the complete report with Table of Contents and List of Figures @https://www.adroitmarketresearch.com/industry-reports/preimplantation-genetic-testing-market

Preimplantation genetic testing is a process in which embryos developed outside the womb are tested for particular genetic characteristics, usually genetic abnormalities that cause serious disease, before being transferred to a womans uterus. Preimplantation genetic testing owes its existence to advances in the world of reproductive medicine and genetics that occurred in the late 20th century. Though initially developed as a means to detect serious genetic conditions, preimplantation genetic testing can be used for other purposes. In fact, virtually any of the hundreds of genetic tests now commercially available, and the many more in development, could be used to test embryos. However, socio-ethical concerns regarding preimplantation genetic testing is a major challenge surrounding the market.

The global preimplantation genetic testing market is categorized based on test type and technology. Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization and single-nucleotide polymorphism. Next-generation sequencing held the largest market share in 2018. The benefits of NGS include:

It allows simultaneous analysis of 24 chromosomes with higher resolution It offers the possibility to analyze chromosomal aneuploidy and monogenic diseases (caused by mutations in a single gene) separately or simultaneously in a single assay Reduced analysis time, avoiding the need to freeze the embryos while awaiting results It allows the simultaneous analysis of several embryos on a single test which directly affects the cost of analysis.

Direct purchase the singe user copy @https://www.adroitmarketresearch.com/researchreport/purchase/1483

In 2018, North America was the largest market for preimplantation genetic testing owing to rising number of IVF procedures and substantial adoption of genomic techniques. Moreover, Asia Pacific is projected to grow at a highest pace during the forecast period. Key players of the preimplantation genetic testing market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology among others.

Major points from Table of Contents:1. Introduction2. Research Methodology3. Market Outlook4. Preimplantation genetic testing Market by Test Type, 2015-2025 (USD Million)5. Preimplantation genetic testing Market by Technology, 2015-2025 (USD Million)6. Preimplantation genetic testing Market by Region 2015-2025 (USD Million)7. Competitive Landscape8. Company Profiles9. Appendix

Access research repository of Upcoming Reports @ https://adroitmarketresearch.com/upcoming.html

About Us:Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Link:
Preimplantation Genetic Testing Market to grow at 11.8% CAGR to hit US $1,147.9 million by 2025 Insights on Trends, Growth Drivers, Key Stakeholders,...

Recommendation and review posted by Bethany Smith

Latest updates on Direct-To-Consumer (DTC) Genetic Testing market, a comprehensive study enumerating the latest price trends and pivotal drivers rendering a positive impact on the industry landscape. Further, the report is inclusive of the competitive terrain of this vertical in addition to the market share analysis and the contribution of the prominent contenders toward the overall industry.

Consumers send the company a DNA sample like urine or saliva and collect their results directly from a written report or from a secure website. DTC genetic testing further provides access to people for their genetic information without the need for involving any health insurance company or a healthcare provider in the process.

Direct-to-consumer genetic testing market is anticipated to record a substantial growth rate over the coming years due to ongoing technological advancements. Direct-to-consumer genetic testing differs from typical genetic testing. These genetic tests are marketed directly to consumers through the medium of print advertisements, internet, or television, and can be bought in stores or online.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/3974

DTC genetic testing, home DNA testing, direct-access genetic testing, and at-home genetic testing are other names for direct-to-consumer genetic testing.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/3974

Not all DTC tests are genetic tests, some are helpful in measuring other things like levels of toxins in urine, or levels of proteins in the human body and types of bacteria flora usually referred as microbiome.

The direct-to-consumer genetic testing market is bifurcated in terms of test type, technology, distribution channel, and regional landscape.

Numerous companies are now offering DTC genetic tests for several purposes. The most common tests use genetic deviations to make estimates about health, give information regarding common traits, and also offer clues about an individual's ancestry. There is a rise in a number of companies providing DTC testing together with the range of health conditions and traits covered by these tests.

With respect to test type, the market is classified into predictive testing, nutrigenomic testing, ancestry, and relationship testing, carrier testing, and others. Among these, carrier testing is set to observe around 14% CAGR between 2020 to 2028, owing to the growing cases of rare genetic diseases that is affecting millions of people globally.

Based on technology, the market is segmented into whole genome sequencing (WGS), single nucleotide polymorphism (SNP) chips, and targeted analysis. Among these, SNP chips held around 50% market share, owing to the technology's efficacy and cost-effectiveness.

Based on distribution channel, the market is categorized into online platforms and over the counter. Among these, the over the counter distribution channel is likely to observe a market value of more than $730 million by 2028, owing to the ease for the customers in purchasing a test kit, especially those living in rural areas of developing nations.

From a regional frame of reference, the Latin America direct-to-consumer genetic testing market is anticipated to record a market value of around $377 million by 2028, attributable to the rising awareness about cost-effective genetic testing options among general population.

Major Highlights from Table of contents are listed below for quick lookup into Direct-To-Consumer (DTC) Genetic Testing Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Direct-To-Consumer (DTC) Genetic Testing industryInsights

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/3974

See the original post:
Direct-To-Consumer (DTC) Genetic Testing - Market Share Analysis and Research Report by 2025 - CueReport

Recommendation and review posted by Bethany Smith

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hereditary Testing market.

Trusted Business Insights presents an updated and Latest Study on Hereditary Testing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hereditary Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Hereditary Testing Market

The global hereditary testing market size was valued at USD 5.8 billion in 2019 and is projected to register at a CAGR of 6.3% during the forecast period. The expanding reproductive genetic health space is one of the key market drivers. Key players, such as Natera, have reported a continuous increase in test volumes in womens health genetic testing for inherited conditions. This reflects the growing acceptance of hereditary tests among the population, thereby accelerating the revenue growth.Furthermore, a consistent rise in demand for newborn screening has led to an increase in sales of DNA testing kits. For instance, in November 2019, the Division of Consolidated Laboratory Services (DCLS) of the Virginia Department of General Services screened 7,868 newborns for nearly 31 hereditary and metabolic disorders. Increasing penetration of newborn screening across the globe is further aiding in the revenue growth.

Reforms in genetic testing guidelines have led to inclusion of multigene panel testing for hereditary cancer into clinical practice. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers offers information on some of the cancer risk factors and management recommendations for single and multiple gene panels.Gradual developments in the distribution model is likely to benefit the genetic testing market. Technology providers are playing a crucial role in the market growth by improving their distribution service and increasing the efficiency of technology. Companies are using a cloud-based distribution model to make bioinformatics technology available for use by other laboratories. As of March, 2019, around 14 licensees were using Constellation software commercially for the marketing of Non-invasive Prenatal Testing (NIPT) products.Although these hereditary tests have huge advantages over conventional tests, several industry experts cited the cost and security concerns faced by consumers pertaining to the test. Moreover, lack of effective regulation of the tests is another key area that demands focused efforts. Despite these challenges, the genetic testing market is constantly expanding owing to the advantages of these innovative tests along with improved healthcare outcomes.DiseaseType Insights of Hereditary Testing Market

Product and service offerings with regard to various hereditary cancer testing continue to expand. Entry of major players, such as Quest, in this segment in the recent past, has significantly driven the hereditary testing market. Considering breast cancer genetic testing as a lucrative source of revenue, companies are focusing on business strategies to enhance their presence in this segment.One of the strategies is offering hereditary tests at a price lower than that offered by competitors. For instance, Color Genomics began selling its product for USD 259, whereas similar products offered by Myriad cost around USD 4,000. The increasing affordability of the tests is one of the key drivers of this segment. Furthermore, BRCA1 carriers have an 80% risk of developing breast cancer, which has also accelerated the developments in hereditary cancer testing market.

On the other hand, lung cancer is one of the major cancer forms that has a relatively few number of products. This is because most cases of lung cancer are not related to inherited genetic mutations. Similarly, for cervical cancer, most of the cases are caused by Human Papilloma Virus (HPV) and not genetic mutations. Lack of effective evidence over heritability of cervical cancer are driving the research activities in this market.Prenatal testing, irrespective of the associated risks, is increasingly gaining popularity. The cell-free DNA (cfDNA)-based NIPT testing is considered medically necessary by Anthem Blue Cross and Blue Shield of California. Previously, these players promoted cfDNA-based NIPT testing for trisomys 21, 18, and 13 only in high-risk pregnancies, as determined by maternal age and other factors.

Regional Insights of Hereditary Testing Market

Variations in regulatory frameworks pertaining to genetic tests across the world have significantly impacted the approval and commercialization of tests in the global market. Currently, a wide variety of genetic tests are being provided by several key companies in U.S. as well as several countries in Europe, Asia Pacific, and other regions.Europe accounted for the largest share in terms of revenue in 2019 and is likely to continue its dominance during the forecast period. This can be attributed to presence of key players providing genetic tests, high adoption of advanced treatments, and recommendations provided by government agencies to ensure the quality of hereditary testing services.In September 2019, Blueprint Genetics, a Finnish company, partnered with ARCHIMEDlife, a rare disease diagnostics company, to provide biochemical testing for rare diseases in North America. Through this partnership, both firms planned to diversify their range of genetic disease testing services to serve the customers better. Such initiatives are expected to strengthen the genetic testing scenario for hereditary disorders in North America, thereby accelerating regional revenue generation.

Market Share Insights of Hereditary Testing Market

Understanding the role of genetic mutation in disease occurrence has significantly accelerated the R&D in this market. Various retrospective studies are being carried out to understand the role of inherited mutations in disease pathology, which has led to key diagnostic developers, such as Quest Diagnostics, enter the market. Continuous authorizations and approvals of genetic tests by the government is expected to propel the organic revenue growth of operating companies.Some of the key players engaged in offering services and products in this market are Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.; Twist Bioscience; Sophia Genetics; Fulgent Genetic, Inc.; Medgenome; and CENTOGENE N.V.Furthermore, the expanding product portfolio is indicative of growing competition in the market. Each company is making focused efforts to offer products with competitive advantage. For example, cross-selling efforts by Natera helped the company witness lucrative revenue generation over the past years. The company promotes collective use of Horizon and Panorama products for women who have not undergone carrier screening tests in their first trimester.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Hereditary Testing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global hereditary testing market report on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2019 2030)

Hereditary Cancer Testing

Lung Cancer

Breast Cancer

Colorectal Cancer

Cervical Cancer

Ovarian Cancer

Prostate Cancer

Stomach/Gastric Cancer

Melanoma

Sarcoma

Uterine Cancer

Pancreatic Cancer

Others

Hereditary Non-cancer Testing

Genetic Tests

Cardiac Diseases

Rare Diseases

Other Diseases

Newborn Genetic Screening

Preimplantation Genetic Diagnosis & Screening

Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests

Quick Read Table of Contents of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the rest here:
Hereditary Testing Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 - 3rd Watch News

Recommendation and review posted by Bethany Smith

Preimplantation Genetic Testing Market Overview

The Preimplantation Genetic Testing market report presents a detailed evaluation of the market. The report focuses on providing a holistic overview with a forecast period of the report extending from 2018 to 2026. The Preimplantation Genetic Testing market report includes analysis in terms of both quantitative and qualitative data, taking into factors such as Product pricing, Product penetration, Country GDP, movement of parent market & child markets, End application industries, etc. The report is defined by bifurcating various parts of the market into segments which provide an understanding of different aspects of the market.

The overall report is divided into the following primary sections: segments, market outlook, competitive landscape and company profiles. The segments cover various aspects of the market, from the trends that are affecting the market to major market players, in turn providing a well-rounded assessment of the market. In terms of the market outlook section, the report provides a study of the major market dynamics that are playing a substantial role in the market. The market outlook section is further categorized into sections; drivers, restraints, opportunities and challenges. The drivers and restraints cover the internal factors of the market whereas opportunities and challenges are the external factors that are affecting the market. The market outlook section also comprises Porters Five Forces analysis (which explains buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Preimplantation Genetic Testing) in addition to the market dynamics.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24037&utm_source=JLN&utm_medium=005

Leading Preimplantation Genetic Testing manufacturers/companies operating at both regional and global levels:

Preimplantation Genetic Testing Market Scope Of The Report

This report offers past, present as well as future analysis and estimates for the Preimplantation Genetic Testing market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. The research methodology that is adopted involves multiple channels of research, chiefly primary interviews, secondary research and subject matter expert advice. The market estimates are calculated on the basis of the degree of impact of the current market dynamics along with various economic, social and political factors on the Preimplantation Genetic Testing market. Both positive as well as negative changes to the market are taken into consideration for the market estimates.

Preimplantation Genetic Testing Market Competitive Landscape & Company Profiles

The competitive landscape and company profile chapters of the market report are dedicated to the major players in the Preimplantation Genetic Testing market. An evaluation of these market players through their product benchmarking, key developments and financial statements sheds a light into the overall market evaluation. The company profile section also includes a SWOT analysis (top three companies) of these players. In addition, the companies that are provided in this section can be customized according to the clients requirements.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24037&utm_source=JLN&utm_medium=005

Preimplantation Genetic Testing Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Preimplantation Genetic Testing market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Preimplantation Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Preimplantation Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Preimplantation Genetic Testing Market, By Deployment Model

5.1 Overview

6 Preimplantation Genetic Testing Market, By Solution

6.1 Overview

7 Preimplantation Genetic Testing Market, By Vertical

7.1 Overview

8 Preimplantation Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Preimplantation Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Preimplantation-Genetic-Testing-Market/?utm_source=JLN&utm_medium=005

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Cellular Health Screening-Health Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Preimplantation Genetic Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cell Based Assays Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Preimplantation Genetic Testing Market Growth Trends, Key Players, Competitive Strategies and Forecasts to 2026 - Jewish Life News

Recommendation and review posted by Bethany Smith

The research study Genetic Testing for Consumers (DTC) market 2020 launched by ABRReports.com provides the detailed analysis of the current market status, investment plans, production and consumption, price trends, and analysis by the market player, by region, by type, by application and etc, and custom research can be added according to specific requirements

Get Sample Copy of the report at https://www.abrreports.com/industry-insights/covid-19-impact-on-2020-2026-global-and-regional-genetic-testing-for-consumers-dtc-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version?form=request-report-sample

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth.

The key players covered in the Genetic Testing for Consumers (DTC) Market research report are:By Market Players:MapmygenomeMyHeritageFull Genome CorporationKarmagenesColor GenomicsHelix OpCo LLCIdentigeneEasy DNAFamilytreeDNA (Gene By Gene)Living DNAAncestryGenesis Healthcare23andMePathway Genomics

By TypeCarrier TestingPredictive TestingAncestry & Relationship TestingNutrigenomics TestingOthers

By ApplicationOnline PlatformsOver-the-Counter

Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/covid-19-impact-on-2020-2026-global-and-regional-genetic-testing-for-consumers-dtc-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version

The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Key pointers of the Table of Contents:

Chapter 1 Industry OverviewChapter 2 Global Genetic Testing for Consumers (DTC) Competition by Types, Applications, and Top Regions and CountriesChapter 3 Production Market AnalysisChapter 4 Global Genetic Testing for Consumers (DTC) Sales, Consumption, Export, Import by Regions (2015-2020)Chapter 5 North America Genetic Testing for Consumers (DTC) Market AnalysisChapter 6 East Asia Genetic Testing for Consumers (DTC) Market AnalysisChapter 7 Europe Genetic Testing for Consumers (DTC) Market AnalysisChapter 8 South Asia Genetic Testing for Consumers (DTC) Market AnalysisChapter 9 Southeast Asia Genetic Testing for Consumers (DTC) Market AnalysisChapter 10 Middle East Genetic Testing for Consumers (DTC) Market AnalysisChapter 11 Africa Genetic Testing for Consumers (DTC) Market AnalysisChapter 12 Oceania Genetic Testing for Consumers (DTC) Market AnalysisChapter 13 South America Genetic Testing for Consumers (DTC) Market AnalysisChapter 14 Company Profiles and Key Figures in Genetic Testing for Consumers (DTC) BusinessChapter 15 Global Genetic Testing for Consumers (DTC) Market Forecast (2021-2026)Chapter 16 Conclusions

Purchase the research study @

https://www.abrreports.com/industry-insights/covid-19-impact-on-2020-2026-global-and-regional-genetic-testing-for-consumers-dtc-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version/checkout?option=one

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company that offers market research reports to individuals, organizations, and industries to enhance and strengthen the decision making process. With an associate thoroughgoing list of market research Publishers, we tend to cut across all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trends, information on products, regional market, and keen business insights to our clients.

Contact Us:

Scott HarrisSales ManagerEmail ID: [emailprotected]Phone No.: +1-561-448-7424

The rest is here:
Genetic Testing for Consumers (DTC) Market 2026 Growth Prospects, Key Trends, COVID-19 Business Impact and Future Scenario - Cole of Duty

Recommendation and review posted by Bethany Smith

Direct-Access Genetic Testing Market report has recently added by A2Z Market Research which helps to make informed business decisions. The comprehensive report on global Direct-Access Genetic Testing Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

Get Free Sample Copy of this Report: https://www.a2zmarketresearch.com/sample?reportId=265122

Top Key Players in profiled in this Market:

23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full GenomesThe key questions answered in this report:

The report offers a competitive situation analysis in the Direct-Access Genetic Testing market. The chapter competitive landscape from the report provides the revenue contribution of major market players along with their market share for the last four to five years. Further, a product comparison matrix and differentiating factors analysis are covered in the report. The strategic development analysis includes various recent initiatives taken by the market players such as product launches, partnerships, research initiatives, global expansions and acquisitions are analyzed in the market report. These developments help the readers of the report to make various decisions such as identifying the target customers, competitor product tracking, and strategy analysis to sustain in the competition.

Global Direct-Access Genetic Testing Market Segmentation:

Market Segmentation: By Type

Diagnostic ScreeningPGDRelationship testing

Market Segmentation: By Application

OnlineOffline

Get 20% Discount on First Purchase of this Report: https://www.a2zmarketresearch.com/discount?reportId=265122

The major growth drivers, challenges, and trends influencing the global Direct-Access Genetic Testing market are inspected at length. The report also presents a thorough qualitative and quantitative data affecting to the projected impact of these factors on markets future growth prospects. A number of analysis tools such as Porters five forces analysis and SWOT analysis have been employed to provide an accurate understanding of this market. Also, the report is compiled in a way for the readers and customers to understand better.

Global Direct-Access Genetic Testing Market report provide insights on following points:

Table of Contents

Global Direct-Access Genetic Testing Market Research Report 2020 2026

Chapter 1 Direct-Access Genetic Testing Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Direct-Access Genetic Testing Market Forecast

Have Query, Inquire Here: https://www.a2zmarketresearch.com/enquiry?reportId=265122

If you have any special requirements, please let us know and we will offer you the report as you want.

Read the original:
Direct-Access Genetic Testing Market Breaking New Grounds and Touch new Level in Upcoming Year by 23andMe, MyHeritage, LabCorp, Myriad Genetics,...

Recommendation and review posted by Bethany Smith

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Breast Cancer Predictive Genetic TestingMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Breast Cancer Predictive Genetic Testing Market Players to battle Covid-19 Impact.

The Breast Cancer Predictive Genetic TestingMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Breast Cancer Predictive Genetic Testing market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Breast Cancer Predictive Genetic Testing market.

Top Leading players covered in the Breast Cancer Predictive Genetic Testing market report: Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae and More

Get PDF Sample Report With Impact of COVID-19 on Breast Cancer Predictive Genetic Testing [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/78838

The report offers clear guidelines for players to cement a position of strength in the global Breast Cancer Predictive Genetic Testing market. It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Breast Cancer Predictive Genetic Testing market will showcase a steadyCAGR in the forecast year 2020 to 2026.

Market Segment by Type covers:High Penetrant GenesIntermediate Penetrant GenesLow Penetrant Genes

Market Segment by Application covers:HospitalsClinicsOthers

Our Complimentary Sample Breast Cancer Predictive Genetic Testing market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here!https://www.marketinforeports.com/Market-Reports/Request_discount/78838

Regions Covered in the Global Breast Cancer Predictive Genetic Testing Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Breast Cancer Predictive Genetic Testing Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2026 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Breast Cancer Predictive Genetic Testing market Exhaustive research on innovation and other trends of the global Breast Cancer Predictive Genetic Testing market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/78838/Breast-Cancer-Predictive-Genetic-Testing-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/78838/Breast-Cancer-Predictive-Genetic-Testing-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]Website: http://www.marketinforeports.com

More:
COVID-19 Update: Global Breast Cancer Predictive Genetic Testing Market is Expected to Grow at a Healthy CAGR with top players Roche, Thermo Fisher...

Recommendation and review posted by Bethany Smith

A new UK-Italian genomics alliance promises to leverage Cambridge artificial intelligence to transform cancer patient management, treatment and monitoring.

Cambridge Cancer Genomics (CCG.ai) has joined forces with Abruzzo-based Dante Labs, a pioneer and leader in genomic testing, and Birmingham business Nonacus which provides genetic testing products for precision medicine and liquid biopsy.

CCG.ai, a software developer specialising in data-driven precision oncology, says the partnership aims to build the most comprehensive and patient-centric tumour profiling service.

By combining Dante Labs experience and capacity in delivering a sequencing service for both solid tumour and cell free circulating tumour DNA from liquid biopsies, Nonacus sensitive targeted pan-cancer NGS libraries, and CCG.ais industry AI-powered software platform, OncOS, the companies will enable precision oncology at scale.

Improving outcomes for cancer patients means ensuring they have the right drug, at the right time to beat their cancer. This means understanding the molecular profile of the individual cancer and using that data to recommend treatments or clinical trials.

Oncologists and clinical researchers will be able to send samples for processing to Dante Labs, who will use library preparation kits from Nonacus and software from CCG.ai to create a sample to report solution.

If there are actionable mutations, the report will recommend the right treatments for those mutations; if there are novel or unactionable mutations the software will also be able to match possible clinical trials.

Nirmesh Patel, CSO at Cambridge Cancer Genomics, said: With cancer being one of the greatest healthcare challenges we are facing, this partnership opens the door to democratising access to data-driven cancer treatment.

Combining our industry leading precision oncology platform with Nonacus precise NGS solutions and Dante Labs fast and efficient NGS services provides customers with the ability to perform precision oncology at scale.

The combined solution will enable oncologists to precisely and comprehensively profile a patients tumour and ultimately improve outcomes.

Chris Sale, CEO of Nonacus, pointed out that COVID-19 had increased the backlog of genetic testing for cancer, potentially leaving many suspected cancers unconfirmed and treatments delayed.

He said: Long turn-around time and lack of clinically oriented analysis are the main obstacles to fully deliver the potential of cancer genomics to patients.

This partnership will provide the flexibility and accuracy that oncology professionals need to integrate cancer genomics into the care of their patients. Only by developing comprehensive content at scale will it be possible to address the COVID backlog.

Dr Mattia Capulli and Andrea Riposati of Dante Labs

Gianmarco Contino of Dante Labs described the venture as the beginning of a revolution in cancer treatment. Until now we have been treating cancer by tissue of origin.

But each cancer harbours a unique combination of mutation which makes it effectively a rare disease. Therefore the right approach should be to start from the mutations and look for the right drugs.

There is a great deal we can learn from sequencing cancer genomes: not only what therapy is going to be more effective but also safer and less toxic. We are now at a stage where a patient can benefit directly from this knowledge. Machine learning is helping us to unleash the potential of information hidden in the complexity of the genome.

See more here:
UK-Italy genomics venture to scale precision oncology - Business Weekly

Recommendation and review posted by Bethany Smith

LOS ANGELES, United States: QY Research has recently published a report, titled Global PCR-Based Testing Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global PCR-Based Testing market. It informs readers about key trends and opportunities in the global PCR-Based Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global PCR-Based Testing market.

Key companies operating in the global PCR-Based Testing market include Abbott, Bio-Rad, Bosch Healthcare, GenMark Diagnostics, GSK, Roche, MeMed, Micronics (Sony), Qorvo Biotechnologies, Siemens Healthineers, STMicroelectronics, Veredus Laboratories, Zoetis, Thermo Fisher, QIAGEN, Agilent, Bioer, Biosynex, Esco, Analytik Jena, Techne

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1836736/global-pcr-based-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global PCR-Based Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global PCR-Based Testing Market Segment By Type:

Analyzers/Instruments, Kits/Panels

Global PCR-Based Testing Market Segment By Application:

Diagnosis and Treatment Genetic Testing Cancer Evolutionary Biology Genetic Fingerprint Forensic Research COVID-19 Others Global PCR-Based Testing

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global PCR-Based Testing market.

Key companies operating in the global PCR-Based Testing market include Abbott, Bio-Rad, Bosch Healthcare, GenMark Diagnostics, GSK, Roche, MeMed, Micronics (Sony), Qorvo Biotechnologies, Siemens Healthineers, STMicroelectronics, Veredus Laboratories, Zoetis, Thermo Fisher, QIAGEN, Agilent, Bioer, Biosynex, Esco, Analytik Jena, Techne

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1836736/global-pcr-based-testing-market

TOC

1 Market Overview of PCR-Based Testing1.1 PCR-Based Testing Market Overview1.1.1 PCR-Based Testing Product Scope1.1.2 Market Status and Outlook1.2 Global PCR-Based Testing Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global PCR-Based Testing Market Size by Region (2015-2026)1.4 Global PCR-Based Testing Historic Market Size by Region (2015-2020)1.5 Global PCR-Based Testing Market Size Forecast by Region (2021-2026)1.6 Key Regions, PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.1 North America PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.2 Europe PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.4 Latin America PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa PCR-Based Testing Market Size YoY Growth (2015-2026) 2 PCR-Based Testing Market Overview by Type2.1 Global PCR-Based Testing Market Size by Type: 2015 VS 2020 VS 20262.2 Global PCR-Based Testing Historic Market Size by Type (2015-2020)2.3 Global PCR-Based Testing Forecasted Market Size by Type (2021-2026)2.4 Analyzers/Instruments2.5 Kits/Panels 3 PCR-Based Testing Market Overview by Application3.1 Global PCR-Based Testing Market Size by Application: 2015 VS 2020 VS 20263.2 Global PCR-Based Testing Historic Market Size by Application (2015-2020)3.3 Global PCR-Based Testing Forecasted Market Size by Application (2021-2026)3.4 Diagnosis and Treatment3.5 Genetic Testing3.6 Cancer3.7 Evolutionary Biology3.8 Genetic Fingerprint3.9 Forensic Research3.10 COVID-193.11 Others 4 Global PCR-Based Testing Competition Analysis by Players4.1 Global PCR-Based Testing Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PCR-Based Testing as of 2019)4.3 Date of Key Manufacturers Enter into PCR-Based Testing Market4.4 Global Top Players PCR-Based Testing Headquarters and Area Served4.5 Key Players PCR-Based Testing Product Solution and Service4.6 Competitive Status4.6.1 PCR-Based Testing Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Abbott5.1.1 Abbott Profile5.1.2 Abbott Main Business5.1.3 Abbott Products, Services and Solutions5.1.4 Abbott Revenue (US$ Million) & (2015-2020)5.1.5 Abbott Recent Developments5.2 Bio-Rad5.2.1 Bio-Rad Profile5.2.2 Bio-Rad Main Business and Companys Total Revenue5.2.3 Bio-Rad Products, Services and Solutions5.2.4 Bio-Rad Revenue (US$ Million) (2015-2020)5.2.5 Bio-Rad Recent Development and Reaction to Covid-195.3 Bosch Healthcare5.5.1 Bosch Healthcare Profile5.3.2 Bosch Healthcare Main Business5.3.3 Bosch Healthcare Products, Services and Solutions5.3.4 Bosch Healthcare Revenue (US$ Million) & (2015-2020)5.3.5 GenMark Diagnostics Recent Developments5.4 GenMark Diagnostics5.4.1 GenMark Diagnostics Profile5.4.2 GenMark Diagnostics Main Business5.4.3 GenMark Diagnostics Products, Services and Solutions5.4.4 GenMark Diagnostics Revenue (US$ Million) & (2015-2020)5.4.5 GenMark Diagnostics Recent Developments5.5 GSK5.5.1 GSK Profile5.5.2 GSK Main Business5.5.3 GSK Products, Services and Solutions5.5.4 GSK Revenue (US$ Million) & (2015-2020)5.5.5 GSK Recent Developments5.6 Roche5.6.1 Roche Profile5.6.2 Roche Main Business5.6.3 Roche Products, Services and Solutions5.6.4 Roche Revenue (US$ Million) & (2015-2020)5.6.5 Roche Recent Developments5.7 MeMed5.7.1 MeMed Profile5.7.2 MeMed Main Business and Companys Total Revenue5.7.3 MeMed Products, Services and Solutions5.7.4 MeMed Revenue (US$ Million) (2015-2020)5.7.5 MeMed Recent Development and Reaction to Covid-195.8 Micronics (Sony)5.8.1 Micronics (Sony) Profile5.8.2 Micronics (Sony) Main Business5.8.3 Micronics (Sony) Products, Services and Solutions5.8.4 Micronics (Sony) Revenue (US$ Million) & (2015-2020)5.8.5 Micronics (Sony) Recent Developments5.9 Qorvo Biotechnologies5.9.1 Qorvo Biotechnologies Profile5.9.2 Qorvo Biotechnologies Main Business5.9.3 Qorvo Biotechnologies Products, Services and Solutions5.9.4 Qorvo Biotechnologies Revenue (US$ Million) & (2015-2020)5.9.5 Qorvo Biotechnologies Recent Developments5.10 Siemens Healthineers5.10.1 Siemens Healthineers Profile5.10.2 Siemens Healthineers Main Business5.10.3 Siemens Healthineers Products, Services and Solutions5.10.4 Siemens Healthineers Revenue (US$ Million) & (2015-2020)5.10.5 Siemens Healthineers Recent Developments5.11 STMicroelectronics5.11.1 STMicroelectronics Profile5.11.2 STMicroelectronics Main Business5.11.3 STMicroelectronics Products, Services and Solutions5.11.4 STMicroelectronics Revenue (US$ Million) & (2015-2020)5.11.5 STMicroelectronics Recent Developments5.12 Veredus Laboratories5.12.1 Veredus Laboratories Profile5.12.2 Veredus Laboratories Main Business5.12.3 Veredus Laboratories Products, Services and Solutions5.12.4 Veredus Laboratories Revenue (US$ Million) & (2015-2020)5.12.5 Veredus Laboratories Recent Developments5.13 Zoetis5.13.1 Zoetis Profile5.13.2 Zoetis Main Business5.13.3 Zoetis Products, Services and Solutions5.13.4 Zoetis Revenue (US$ Million) & (2015-2020)5.13.5 Zoetis Recent Developments5.14 Thermo Fisher5.14.1 Thermo Fisher Profile5.14.2 Thermo Fisher Main Business5.14.3 Thermo Fisher Products, Services and Solutions5.14.4 Thermo Fisher Revenue (US$ Million) & (2015-2020)5.14.5 Thermo Fisher Recent Developments5.15 QIAGEN5.15.1 QIAGEN Profile5.15.2 QIAGEN Main Business5.15.3 QIAGEN Products, Services and Solutions5.15.4 QIAGEN Revenue (US$ Million) & (2015-2020)5.15.5 QIAGEN Recent Developments5.16 Agilent5.16.1 Agilent Profile5.16.2 Agilent Main Business and Companys Total Revenue5.16.3 Agilent Products, Services and Solutions5.16.4 Agilent Revenue (US$ Million) (2015-2020)5.16.5 Agilent Recent Development and Reaction to Covid-195.17 Bioer5.17.1 Bioer Profile5.17.2 Bioer Main Business5.17.3 Bioer Products, Services and Solutions5.17.4 Bioer Revenue (US$ Million) & (2015-2020)5.17.5 Bioer Recent Developments5.18 Biosynex5.18.1 Biosynex Profile5.18.2 Biosynex Main Business5.18.3 Biosynex Products, Services and Solutions5.18.4 Biosynex Revenue (US$ Million) & (2015-2020)5.18.5 Biosynex Recent Developments5.19 Esco5.19.1 Esco Profile5.19.2 Esco Main Business5.19.3 Esco Products, Services and Solutions5.19.4 Esco Revenue (US$ Million) & (2015-2020)5.19.5 Esco Recent Developments5.20 Analytik Jena5.20.1 Analytik Jena Profile5.20.2 Analytik Jena Main Business5.20.3 Analytik Jena Products, Services and Solutions5.20.4 Analytik Jena Revenue (US$ Million) & (2015-2020)5.20.5 Analytik Jena Recent Developments5.21 Techne5.21.1 Techne Profile5.21.2 Techne Main Business5.21.3 Techne Products, Services and Solutions5.21.4 Techne Revenue (US$ Million) & (2015-2020)5.21.5 Techne Recent Developments 6 North America6.1 North America PCR-Based Testing Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe PCR-Based Testing Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific PCR-Based Testing Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America PCR-Based Testing Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa PCR-Based Testing Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 PCR-Based Testing Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Trending: PCR-Based Testing Market Segmentation Along With Regional Outlook, Competitive Strategies, Factors Contributing To Growth 2020-2026| -...

Recommendation and review posted by Bethany Smith

Ginalski K, Rychlewski L, Baker D, Grishin NV. Protein structure prediction for the male-specific region of the human Y chromosome. Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2305-10.

Jain M, Olsen HE, Turner DJ, Stoddart D, Bulazel KV, Paten B, Haussler D, Willard HF, Akeson M, Miga KH. Linear assembly of a human centromere on the Y chromosome. Nat Biotechnol. 2018 Mar 19. doi: 10.1038/nbt.4109. [Epub ahead of print]

Krausz C, Casamonti E. Spermatogenic failure and the Y chromosome. Hum Genet. 2017 May;136(5):637-655. doi: 10.1007/s00439-017-1793-8. Epub 2017 Apr 29. Review.

Krausz C, Quintana-Murci L, Forti G. Y chromosome polymorphisms in medicine. Ann Med. 2004;36(8):573-83. Review.

Liu XG, Hu HY, Guo YH, Sun YP. Correlation between Y chromosome microdeletion and male infertility. Genet Mol Res. 2016 Jun 3;15(2). doi: 10.4238/gmr.15028426.

Noordam MJ, Repping S. The human Y chromosome: a masculine chromosome. Curr Opin Genet Dev. 2006 Jun;16(3):225-32. Epub 2006 May 2. Review.

Rizvi AA. 46, XX man with SRY gene translocation: cytogenetic characteristics, clinical features and management. Am J Med Sci. 2008 Apr;335(4):307-9. doi: 10.1097/MAJ.0b013e31811ec1b4.

Russo P, Siani A, Miller MA, Karanam S, Esposito T, Gianfrancesco F, Barba G, Lauria F, Strazzullo P, Cappuccio FP. Genetic variants of Y chromosome are associated with a protective lipid profile in black men. Arterioscler Thromb Vasc Biol. 2008 Aug;28(8):1569-74. doi: 10.1161/ATVBAHA.108.168641. Epub 2008 May 29.

Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, Brown LG, Repping S, Pyntikova T, Ali J, Bieri T, Chinwalla A, Delehaunty A, Delehaunty K, Du H, Fewell G, Fulton L, Fulton R, Graves T, Hou SF, Latrielle P, Leonard S, Mardis E, Maupin R, McPherson J, Miner T, Nash W, Nguyen C, Ozersky P, Pepin K, Rock S, Rohlfing T, Scott K, Schultz B, Strong C, Tin-Wollam A, Yang SP, Waterston RH, Wilson RK, Rozen S, Page DC. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature. 2003 Jun 19;423(6942):825-37.

Tartaglia N, Davis S, Hench A, Nimishakavi S, Beauregard R, Reynolds A, Fenton L, Albrecht L, Ross J, Visootsak J, Hansen R, Hagerman R. A new look at XXYY syndrome: medical and psychological features. Am J Med Genet A. 2008 Jun 15;146A(12):1509-22. doi: 10.1002/ajmg.a.32366.

Visootsak J, Graham JM Jr. Klinefelter syndrome and other sex chromosomal aneuploidies. Orphanet J Rare Dis. 2006 Oct 24;1:42. Review.

Visootsak J, Rosner B, Dykens E, Tartaglia N, Graham JM Jr. Behavioral phenotype of sex chromosome aneuploidies: 48,XXYY, 48,XXXY, and 49,XXXXY. Am J Med Genet A. 2007 Jun 1;143A(11):1198-203.

Walzer S, Bashir AS, Silbert AR. Cognitive and behavioral factors in the learning disabilities of 47,XXY and 47,XYY boys. Birth Defects Orig Artic Ser. 1990;26(4):45-58.

Waters PD, Wallis MC, Marshall Graves JA. Mammalian sex--Origin and evolution of the Y chromosome and SRY. Semin Cell Dev Biol. 2007 Jun;18(3):389-400. Epub 2007 Feb 24. Review.

Willard HF. Tales of the Y chromosome. Nature. 2003 Jun 19;423(6942):810-1, 813.

Originally posted here:
Y chromosome - Genetics Home Reference - NIH

Recommendation and review posted by Bethany Smith

The study on Global Male Breast Cancer Market, offers deep insights about the Male Breast Cancer Market covering all the crucial aspects of theMarket. Some of the important aspects analyzed in the reportincludesMarket share, production, key regions, revenue rate as well as key players. This Male Breast Cancer report also provides the readers with detailed figures at which the Male Breast Cancer Market was valued in the historical year and its expected growth in upcoming years. Besides, analysis also forecasts the CAGR at which the Male Breast Cancer is expected to mount and major factors driving Markets growth. This Male Breast Cancer Market was accounted for USD xxx million in the historical year and isestimated to reach at USD xxx million by the end of the forecast period, rising at a CAGR of xx%.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4697601?utm_source=Ancy

Market research reports play anextremely important role in refining the productivity of anindustry. The information in this reports will help the companies to make informed Marketing strategies. Moreover,ultimate goal of Market research is to analyze how the Markets target group will obtain a product or service. Market research report is predominantly prepared following certain methodology and guidelines for collecting, organizing and analyzing data. The research report on Global Male Breast Cancer Market has been very well drafted for the benefit of the readers who are looking forward to invest in the Market. Besides, focusing on overall aspects of the Market this report majorly covered profiles of the top big companies along with their sales data, etc.It also delivers the business models, strategies, growth, innovations and every information about key manufacturers that will enable in making business estimates.

Major companies of this report:

PfizerRocheGlaxoSmithKlineSanofiNovartisBayerBristol-Myers SquibbEli LillyAstraZenecaTeva PharmaceuticalSun PharmaceuticalBioNumerik PharmaceuticalsSeattle GeneticsAccord Healthcare

Browse the complete report @ https://www.orbisresearch.com/reports/index/male-breast-cancer-market-research-global-status-and-forecast-by-geography-type-and-application-2016-2026?utm_source=Ancy

In addition, every Market has a set of manufacturers, vendors and consumers that define the Market as well as their every moves and achievements becomes a subject of studying for Market analysts. Moreover, reports offers Market competition through region segmentation of Markets that enables in thorough analysis of the Market in terms of revenue generation potential, demand & supply comparison, business opportunities and future estimates of the Market. The annual progression for the Global Male Breast Cancer Market in different regions cannot always be listed down as it will keep changing, thus studying and reviewing Markets occasionally becomes vital. Major regions highlighted for the Global Male Breast Cancer Market report, include North America, South America, Asia, Europe and Middle East.

Segmentation by Type:

MedicationChemotherapyOthers

Segmentation by Application:

HospitalsClinicsOthers

Market research report on the Global Male Breast Cancer Market, also has the Market analyzed on the basis of different end user applications and type. End user application segments analysis allowsdefining the consumer behavior as well. It ishelpful to investigate product application in order toforetell the products outcome. Analyzing different segment type is also crucial aspect. It helps determine which type of the product orservice needs improvement. When reports are product centric, they also includes information about sales channel, distributors, traders as well as dealers. This facilitates effective planning as well as execution of the supply chain management. In a nutshell, a Market research report is through guide of a Market that aids the better Marketing and management of businesses.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4697601?utm_source=Ancy

About Us :

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us :

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: +1 (972)-362-8199; +91 895 659 5155

Read the original here:
Global Male Breast Cancer Market 2020 by Type of Service Offered, Manufacture, Statistics, Share, Growth, Revenue, Regions, and Business Opportunities...

Recommendation and review posted by Bethany Smith

SOUTH BEND, Ind. Clark Lea started texting and calling, wanting to talk but needing to listen. When he got to Daelin Hayes, the conversation compelled Lea to do more.

Notre Dames defensive coordinator had already seen the video of George Floyd under the knee of Minneapolis police officer Derek Chauvin. He had followed from a distance as anger at Floyds death boiled over in protests across the country. Lea didnt have a solution for any of it, other than to reach out to his players.

The words of Notre Dames fifth-year defensive end stopped Lea cold. They talked about Hayes life experience and the reality that faces Notre Dames defensive roster, where black players make up a majority. Hayes took those experiences and translated them for Lea, who has three kids.

Imagine sending your son out into the world and it sees him as a threat, Hayes told Lea. And you dont know if hes gonna...

More:
How Notre Dame empowered its players to speak out, and why it needs to listen - The Athletic

Recommendation and review posted by Bethany Smith

CRISPR Therapeutics and Vertex have presented updated data on the first patients treated with their CRISPR/Cas9 gene-editing therapy. The partners now have evidence that one-time treatment with CTX001 improves outcomes in sickle cell disease and beta thalassemia patients for up to 15 months.

In November, CRISPR and Vertex moved the gene-editing field beyond an early milestone by linking the use of CTX001 to sustained improvements in the health and biomarkers of two patients with the severe hemoglobinopathies sickle cell disease and transfusion-dependent beta thalassemia. Late last week, the partners used the European Hematology Association virtual congress to share an update on the studies.

CRISPR and Vertex now have data on two beta thalassemia patients. The first patient, who had nine months of follow up as of last years update, has now been tracked out to 15 months after treatment with CTX001. The patients levels of total hemoglobin, fetal hemoglobin and erythrocytes expressing fetal hemoglobin (F-cells) increased between the two updates.

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

The partners also have five-month data on a second beta thalassemia patient. The hemoglobin and F-cell levels of the second patient are close to or above those of the first patient at the nine-month mark. Both patients experienced two serious adverse events, none of which the investigator considered to be related to CTX001.

CRISPR and Vertex also used the virtual event to share a nine-month update on a sickle cell patient. Compared to the four-month readout, total hemoglobin and F-cells are up. Fetal hemoglobin is down slightly, but still well above the level likely needed to be efficacious.

The improved biomarker data are supported by evidence the drug is making a meaningful difference to the lives of the patients. The beta thalassemia patients are transfusion independent, having required 34 and 61 units of packed red blood cells a year previously. The subject who required 34 blood units underwent 33 transfusions over the two years before consenting to join the study.

In the sickle cell trial, the patient used to suffer seven vaso-occlusive crises a year, on average. Over the nine months in the study, the patient has been free from vaso-occlusive crises.

The data, which the author of the abstract said demonstrate a functional cure, support the further assessment of CTX001. Efforts to gather more data were hindered by COVID-19, which led to the temporary cessation of elective hematopoietic stem cell transplants at sites in the U.S. and Europe. Some sites are now gearing up to reinitiate dosing.

Even if the restart progresses slowly, CRISPR and Vertex will still be in a position to share more data later in the year. Investigators dosed another three beta thalassemia patients and one sickle cell patient before COVID-19 hit, setting them up to share updates as those subjects pass follow-up milestones.

The updates should also feature longer-term data on the first three patients treated in the trials. In posting long-term data, CRISPR and Vertex will begin to show whether CTX001 has the durability to be a true one-time treatment and, in doing so, carve out a space in a market fought over by rivals such as bluebird bio.

Originally posted here:
CRISPR and Vertex show durability of gene-editing therapy, hoping for one and done treatment - FierceBiotech

Recommendation and review posted by Bethany Smith

New Jersey, United States,- A detailed research study on CRISPR and Cas Genes Market recently published by Verified Market Research. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of CRISPR and Cas Genes, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Leading CRISPR and Cas Genes manufacturers/companies operating at both regional and global levels:

CRISPR and Cas Genes Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the CRISPR and Cas Genes market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global CRISPR and Cas Genes market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40530&utm_source=COD&utm_medium=007

CRISPR and Cas Genes Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the CRISPR and Cas Genes market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of CRISPR and Cas Genes Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 CRISPR and Cas Genes Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 CRISPR and Cas Genes Market, By Deployment Model

5.1 Overview

6 CRISPR and Cas Genes Market, By Solution

6.1 Overview

7 CRISPR and Cas Genes Market, By Vertical

7.1 Overview

8 CRISPR and Cas Genes Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 CRISPR and Cas Genes Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/crispr-and-cas-genes-market/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Mobile Data Protection Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Activated Carbon Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Smart City ICT Infrastructure Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
CRISPR and Cas Genes Market Analysis, Trends, Top Manufacturers, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith